Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6834d33b470141e1641f18b6fcf9e878> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6834d33b470141e1641f18b6fcf9e878 NCIT_P378 "NCI" @default.
- B6834d33b470141e1641f18b6fcf9e878 type Axiom @default.
- B6834d33b470141e1641f18b6fcf9e878 annotatedProperty IAO_0000115 @default.
- B6834d33b470141e1641f18b6fcf9e878 annotatedSource NCIT_C199581 @default.
- B6834d33b470141e1641f18b6fcf9e878 annotatedTarget "An orally bioavailable fixed combination of the sodium salt form of dolutegravir, an integrase strand-transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of dolutegravir/lamivudine, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Lamivudine is phosphorylated into its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), which inhibits the HIV reverse transcriptase (RT) enzyme competitively and acts as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions." @default.